Business Model Breakdown
How Accuray Inc Makes Money
ARAY
Market Cap
$52M
Annual Revenue
$102M
Profit Margin
-8.2%
The Short Version
Accuray Inc. designs, develops, and sells advanced radiation therapy systems used for treating cancer and other medical conditions. Their two primary product lines are the CyberKnife and TomoTherapy systems, which deliver highly precise radiation to tumors. The company generates revenue by selling these high-capital medical devices to hospitals and cancer treatment centers globally. Additionally, a significant portion of its revenue comes from recurring service contracts, maintenance agreements, software upgrades, and parts sales for its installed base of systems.
Where the Revenue Comes From
Service revenue (~56% of Q2 2026 total revenue)
Product revenue (~44% of Q2 2026 total revenue)
Who buys: Global hospitals, cancer treatment centers, and academic medical institutions.
Why It Works (Competitive Advantages)
- ✔Proprietary, highly specialized radiation therapy technology (CyberKnife, TomoTherapy)
- ✔Established installed base and associated service revenue stream
- ✔High switching costs for existing customers due to system complexity and capital investment
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs)
What Our Analysis Says
DVR Score as of April 23, 2026
Accuray Inc. presents an extremely high-risk, high-reward profile typical of deeply distressed micro-caps. Its specialized radiation oncology technology (CyberKnife, TomoTherapy) addresses a growing market, offering a theoretical high-upside if a monumental turnaround or acquisition occurs. However, recent Q2 2026 earnings showed a revenue miss and year-over-year decline, alongside a net loss, reinforcing significant execution challenges and precarious financial health. The most critical new development is the Nasdaq non-compliance notice due to the stock trading below $1, posing a delisting risk. High debt-to-equity (254.4%) and persistent losses underscore the financial fragility. While there's a slim chance of a strategic pivot or acquisition unlocking value, the probability of 10x growth within 3-5 years is severely hampered by ongoing operational struggles and existential market listing risks, making it highly speculative.